Curemark is a biopharmaceutical company focused on the development of novel therapies to treat serious diseases for which there are limited treatment options. Curemark blends a unique business model with an expert team to bring promising medical technologies to patients.

Our pipeline includes two Phase III clinical-stage programs for Autism and ADHD as well as three preclinical programs for Parkinson’s, Schizophrenia and Addiction. All of our product candidates address severe neurologic diseases that are underserved by available approved therapies and represent large potential commercial opportunities. We believe that our product candidates offer innovative therapeutic approaches and may have the potential to provide significant advantages relative to current therapies.